Yaping Shou

4.8k citations
68 papers · 3.1k · 1 hit paper · h-index 26

Impact in

  • Hematology top 0.5%
    • Chronic Myeloid Leukemia Treatments
    • Multiple Myeloma Research and Treatments
  • Genetics top 0.5%
    • Chronic Lymphocytic Leukemia Research

Papers in

  • Genetics 32
    • Chronic Lymphocytic Leukemia Research 31
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 5
  • Hematology 31
    • Chronic Myeloid Leukemia Treatments 24
    • Multiple Myeloma Research and Treatments 5
Co-authors
Andreas Hochhaus (22 shared papers)Francis J. Giles (7 shared papers)Hagop M. Kantarjian (13 shared papers)Md Ariful Haque (9 shared papers)Giuseppe Saglio (19 shared papers)Timothy P. Hughes (18 shared papers)Norbert Gattermann (4 shared papers)Kapil N. Bhalla (3 shared papers)
Journals
Blood (25 papers)Journal of Clinical Oncology (14 papers)Clinical Cancer Research (2 papers)Haematologica (2 papers)Future Oncology (2 papers)
Partner nations
United StatesItalyGermany

In The Last Decade

Yaping Shou

67 papers receiving 3.1k citations

Yaping Shou's Hit Papers

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance 2007 · 542 citations
5420+6+12Years since publication100200300400500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2007 Blood

Peers

Yaping Shou
Comparison fields: 5 of 91
  • Hematology 1.8k
  • Genetics 1.2k
  • Rheumatology 639
  • Pathology and Forensic Medicine 390
  • Oncology 580
Replace Hans D. Menssen with:
Hans D. Menssen United States
Elisabetta Abruzzese Italy
Tetsuzo Tauchi Japan
Cox Eb United States
Zariana Nikolova Switzerland
Shu Tamura Japan
Kathryn S. Kolibaba United States
Ramón V. Tiu United States
Loïc Garçon France
Alejandro Martı́n Spain
Yaping Shou relative to Hans D. Menssen United States Hans D. Menssen's profile →
Citations per field
00.5×1.5×2.1×
Hans D. Menssen · 1×
Citations per year

Countries citing papers authored by Yaping Shou

Since Specialization
Citations

This map shows the geographic impact of Yaping Shou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yaping Shou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yaping Shou more than expected).

Fields of papers citing papers by Yaping Shou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yaping Shou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yaping Shou. The network helps show where Yaping Shou may publish in the future.

Co-authors

The 25 scholars most cited alongside Yaping Shou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yaping Shou Line = papers co-authored together Yaping Shou links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Blood ·Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann, Kapil N. Bhalla, Giuliana Alimena, Francesca Palandri, Gert J. Ossenkoppele, Franck-Emmanuel Nicolini, Stephen G. O’Brien, Mark R. Litzow, Ravi Bhatia, Francisco Cervantes, Md Ariful Haque, Yaping Shou, Debra Resta, Aaron Weitzman, Andreas Hochhaus, Philipp le Coutre
Hit paper breakdown →		2007542
2
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Blood ·Hagop M. Kantarjian, Francis J. Giles, Kapil N. Bhalla, Javier Pinilla‐Ibarz, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Andreas Hochhaus, Jerald P. Radich, Giuseppe Saglio, Timothy P. Hughes, Giovanni Martinelli, Dong-Wook Kim, Yaping Shou, Neil J. Gallagher, Rick E. Blakesley, Michele Baccarani, Jörge E. Cortes, Philipp D. le Coutre
2010273
3
Diverse karyotypic abnormalities of the c -myc locus associated with c -myc dysregulation and tumor progression in multiple myeloma
Proceedings of the National Academy of Sciences ·Yaping Shou, Marialuisa Martelli, Ana Gabrea, Qi Ying, Leslie A. Brents, Anna V. Roschke, Gordon W. Dewald, Ilan R. Kirsch, P. Leif Bergsagel, W. Michael Kuehl
2000266
4
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Journal of Clinical Oncology ·Timothy P. Hughes, Giuseppe Saglio, Susan Branford, Simona Soverini, Dong‐Wook Kim, Martin C. Müller, Giovanni Martinelli, Jörge E. Cortes, Lan Beppu, Enrico Gottardi, Dong‐Ho Kim, Philipp Erben, Yaping Shou, Md Ariful Haque, Neil J. Gallagher, Jerald P. Radich, Andreas Hochhaus
2009236
5
A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
Clinical Cancer Research ·Jordi Rodón, Hussein Tawbi, Anne Thomas, Ronald G. Stoller, Christian P. Turtschi, José Baselga, John Sarantopoulos, Devalingam Mahalingam, Yaping Shou, Melissa A. Moles, Lin Yang, Camille Granvil, Eunju Hurh, Kristine Rose, Dereck D. Amakye, Reinhard Dummer, Alain C. Mita
2014187
6
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
Blood ·Shaji Kumar, William Bensinger, Todd M. Zimmerman, Craig B. Reeder, James R. Berenson, Deborah Berg, Ai-Min Hui, Neeraj Gupta, Alessandra Di Bacco, Yu Jiang, Yaping Shou, Rubén Niesvizky
2014158
7
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
Leukemia ·Jonathan B. Singer, Yaping Shou, Francis J. Giles, H Kantarjian, Yanzhi Hsu, Anna Robeva, P. Rae, Aaron Weitzman, Joanne M. Meyer, Margaret Dugan, Oliver G. Ottmann
200792
8
PPARγ activation enhances cell surface ENaCα via up‐regulation of SGK1 in human collecting duct cells
The FASEB Journal ·Guizhu Hong, Andrew Lockhart, Bill Davis, Hassan Rahmoune, Sharon F. Baker, Ye Liang, Paul Thompson, Yaping Shou, Kevin M. O’Shaughnessy, Pierre Ronco, John Brown
200390
9
Targeting CD47 in Sézary syndrome with SIRPαFc
Blood Advances ·Lisa D. Johnson, Swati Banerjee, Oleg Kruglov, Natasja Nielsen Viller, Sarah McCue Horwitz, Alexander M. Lesokhin, Jasmine Zain, Christiane Querfeld, Robert Chen, Craig Okada, Ahmed Sawas, Owen A. O’Connor, Eric L. Sievers, Yaping Shou, Robert A. Uger, Mark Wong, Oleg E. Akilov
201985
10
Insertion of Excised IgH Switch Sequences Causes Overexpression of Cyclin D1 in a Myeloma Tumor Cell
Molecular Cell ·Ana Gabrea, P. Leif Bergsagel, Marta Chesi, Yaping Shou, W. Michael Kuehl
199985
11
An Ets/Sp1 interaction in the 5'-flanking region of the megakaryocyte- specific alpha IIb gene appears to stabilize Sp1 binding and is essential for expression of this TATA-less gene
Blood ·KL Block, Yaping Shou, M Poncz
199684
12
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
Clinical Cancer Research ·Dejan Juric, Johann S. de Bono, Patricia LoRusso, John Nemunaitis, Elisabeth I. Heath, Eunice L. Kwak, T. Macarulla Mercadé, Elena Geuna, Maria J. de Miguel, Chirag Patel, Keisuke Kuida, Serap Sankoh, Eric H. Westin, Fabian Zohren, Yaping Shou, Josep Tabernero
201777
13
Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
Journal of Clinical Oncology ·Susan Branford, Dong‐Wook Kim, Simona Soverini, Md Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, Martin C. Müller
201274
14
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
British Journal of Cancer ·Martin H. Voss, Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla, David C. Smith, Andrés Cervantes, Igor Puzanov, Роберто Пили, Ding Wang, Shadia I. Jalal, Shubham Pant, Manish R. Patel, Rachel Neuwirth, Aaron Enke, Yaping Shou, Farhad Sedarati, Douglas V. Faller, Howard A. Burris
202068
15
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells
Blood ·Vivian G. Oehler, Katherine A. Guthrie, Carrie L. Cummings, Kathleen M. Sabo, Brent L. Wood, Ted Gooley, Taimei Yang, Mirjam T. Epping, Yaping Shou, Era L. Pogosova‐Agadjanyan, Paula Ladne, Derek L. Stirewalt, Janis L. Abkowitz, Jerald P. Radich
200965
16
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Blood ·Andreas Hochhaus, Giuseppe Saglio, Richard A. Larson, Dong‐Wook Kim, Gabriel Étienne, Gianantonio Rosti, Cármino Antônio De Souza, Mineo Kurokawa, Matt Kalaycio, Albert Hoenekopp, Xiaolin Fan, Yaping Shou, Hagop M. Kantarjian, Timothy P. Hughes
201364
17
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
Leukemia ·Philipp D. le Coutre, Francis J. Giles, Andreas Hochhaus, Jane F. Apperley, G. J. Ossenkoppele, Rick E. Blakesley, Yaping Shou, Neil J. Gallagher, Michele Baccarani, Jörge E. Cortes, Hagop M Kantarjian
201163
18
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study
The Lancet Haematology ·Christiane Querfeld, John A. Thompson, Matthew H. Taylor, Jennifer DeSimone, Jasmine Zain, Andrei R. Shustov, Carolyn Johns, Sue McCann, Gloria H. Y. Lin, Penka S. Petrova, Robert A. Uger, Naomi Molloy, Yaping Shou, Oleg E. Akilov
202162
19
An Sp1-binding Silencer Element Is a Critical Negative Regulator of the Megakaryocyte-specific αIIb Gene
Journal of Biological Chemistry ·Yaping Shou, Shira Baron, Mortimer Poncz
199845
20
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
Blood Cancer Journal ·Sarit Assouline, Elizabeth Chang, Bruce D. Cheson, Robert M. Rifkin, Solomon I. Hamburg, Ruben Reyes, A-M Hui, Jie Yu, Neeraj Gupta, Alessandra Di Bacco, Yaping Shou, Peter Martin
201444

About Yaping Shou

Yaping Shou is a scholar working on Genetics, Hematology, Molecular Biology, Oncology and Immunology, having authored 68 papers that have together received 3.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (31 papers), Chronic Myeloid Leukemia Treatments (24 papers), Lymphoma Diagnosis and Treatment (11 papers), CAR-T cell therapy research (9 papers), Eosinophilic Disorders and Syndromes (8 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Multiple Myeloma Research and Treatments (5 papers). The work is most often cited by research in Hematology (1.8k citations), Genetics (1.2k citations), Rheumatology (639 citations), Pathology and Forensic Medicine (390 citations) and Oncology (580 citations). Yaping Shou has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Andreas Hochhaus, Francis J. Giles, Hagop M. Kantarjian, Md Ariful Haque, Giuseppe Saglio, Timothy P. Hughes, Norbert Gattermann, Kapil N. Bhalla, Jerald P. Radich and W. Michael Kuehl. Their work appears in journals such as Blood, Journal of Clinical Oncology, Clinical Cancer Research, Haematologica and Future Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans D. MenssenBreakdown of academic impact, for papers by Elisabetta AbruzzeseBreakdown of academic impact, for papers by Tetsuzo TauchiBreakdown of academic impact, for papers by Cox EbBreakdown of academic impact, for papers by Zariana NikolovaBreakdown of academic impact, for papers by Shu TamuraBreakdown of academic impact, for papers by Kathryn S. KolibabaBreakdown of academic impact, for papers by Ramón V. TiuBreakdown of academic impact, for papers by Loïc GarçonBreakdown of academic impact, for papers by Alejandro Martı́n